Ackman's foundation spends $260m on Manhattan brain hub
Billionaire investor Bill Ackman is deploying $260 million to acquire a Manhattan life sciences campus, capitalizing on a sector downturn to launch a massive brain research institute backed by a planned venture ecosystem.
Bill Ackman’s Pershing Square Foundation has closed a $260 million real estate acquisition to establish the Ackman Oxman Institute on Manhattan’s Upper West Side. The core purchase is a 400,000-square-foot property at 125 West End Avenue, currently known as West End Labs, bought for $190 million. The foundation also signed a $70 million contract for an adjoining building at 320 West 66th Street.
With the addition of purchased development rights, the completed campus could encompass nearly 700,000 square feet. At that scale, the facility would eclipse established New York City health research centers, including the Rockefeller Institute for Medical Research. The deal closed on Tuesday morning.
The transaction capitalizes directly on a recent slump in the life sciences real estate market. Ackman and his wife, Neri Oxman, first eyed the West End Avenue site five years ago following the death of Oxman’s mother to Alzheimer’s. At that time, the cost of the real estate and the talent required to staff a major institute were prohibitively high.
A shifting market for scientific talent altered the economics. Ackman pointed to a growing willingness among researchers to exit academia, combined with depressed life science property valuations, as the key factors that made the $260 million deployment viable. The decision to move forward was ultimately accelerated by a family emergency in February.
That month, Ackman’s 26-year-old daughter suffered a brain hemorrhage and was discovered 15 hours later. Her survival, aided by experimental treatments championed by Ackman, served as the catalyst to finalize the plans. The new institute will use insights from her care as a foundation for broader research into neurosurgery, rehab, longevity, and nutrition.
To execute the scientific strategy, the institute will operate in partnership with Mount Sinai hospital. The board of directors features Nobel Prize-winning cell researcher Jim Rothman and Stanford neuroscientist Andrew Huberman. The organization is currently searching for a CEO and expects to begin operations in the main building before the end of the year.
The initial capital outlay comes from Pershing Square Philanthropies, which has allocated more than $1 billion to date. However, the long-term financial model relies heavily on commercializing the research. Ackman stated that future funding will be driven by an ecosystem of startups and venture capital attached to the institute.
